Literature DB >> 2159261

(+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses.

A K Field1, A V Tuomari, B McGeever-Rubin, B J Terry, K E Mazina, M L Haffey, M E Hagen, J M Clark, A Braitman, W A Slusarchyk.   

Abstract

(+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine [(+-)-BHCG or SQ 33,054] is a newly synthesized nucleoside analog with potent and selective antiviral activity against members of the herpesvirus group, including human cytomegalovirus. The activity against a thymidine kinase deficient HSV-2 mutant was 25-fold poorer than against the parent virus, suggesting that phosphorylation is an important prerequisite for antiviral activity against HSV-2. (+-)-BHCG is readily phosphorylated by purified HSV-1 thymidine kinase, and BHCG triphosphate synthesized enzymatically is a selective inhibitor of HSV-1 DNA polymerase. (+-)-BHCG did not inhibit host cell growth at concentrations at least 1000-fold higher than HSV-2 inhibitory concentrations. Subcutaneous administration of (+-)-BHCG was protective against HSV-1 systemic infections in mice. BHCG is an exciting antiviral agent and represents a new class of nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159261     DOI: 10.1016/0166-3542(90)90043-7

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers.

Authors:  H Shiota; K Nitta; T Naito; Y Mimura; T Maruyama
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 2.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.

Authors:  D J Tenney; G Yamanaka; S M Voss; C W Cianci; A V Tuomari; A K Sheaffer; M Alam; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

4.  Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.

Authors:  S F Innaimo; M Seifer; G S Bisacchi; D N Standring; R Zahler; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.938

Review 5.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

7.  Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice.

Authors:  A Braitman; M R Swerdel; S J Olsen; A V Tuomari; J S Lynch; B Blue; T Michalik; A K Field; D P Bonner; J M Clark
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

Authors:  M Seifer; R K Hamatake; R J Colonno; D N Standring
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.938

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.